Cook Biotech
Cook Biotech develops and manufactures porcine Small Intestinal Submucosa (SIS)-based regenerative biomaterial scaffolds for soft-tissue and peripheral nerve repair, operating as a CDMO supplying OEM medical-device companies across multiple surgical specialties. The company was acquired by RTI Surgical in January 2024.
- Company typePrivate
- Founded1998
- HeadquartersWest Lafayette, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cook Biotech does
Cook Biotech Incorporated is a regenerative biomaterials company specializing in xenograft products derived from porcine Small Intestinal Submucosa (SIS). Founded in 1998 and headquartered in West Lafayette, Indiana, the company developed a proprietary SIS-based platform that serves as a biologic scaffold for regenerative soft-tissue repair and peripheral nerve-repair applications. The technology is positioned to support the body's natural healing process across a range of surgical uses, with the company having achieved 200+ market authorizations and 50+ 510(k) clearances cumulatively, and 20M+ implants delivered worldwide.
The company's business model is best characterized as a contract development and manufacturing organization (CDMO) serving original equipment manufacturer (OEM) customers in the medical-device industry. Cook Biotech partners with surgical and medical-device companies to design, develop, and manufacture customized SIS-based biomaterial solutions for use in plastic and reconstructive surgery, sports medicine and orthopedics, neuro/spine, and cardiac applications. Revenue is generated through OEM supply agreements and contract manufacturing relationships rather than direct-to-hospital or direct-to-physician sales. Pricing is not publicly disclosed.
In January 2024, Cook Biotech was acquired by RTI Surgical, which subsequently positioned the combined regenerative-medicine operations under the Evergen brand, framing the business as a global regenerative CDMO. Following the acquisition, Cook Biotech no longer operates as an independent entity; its SIS technology and OEM relationships are now integrated into RTI Surgical's/Evergen's broader biomaterials and contract-manufacturing portfolio. The company employs 101-250 people and is privately held under its parent operating company.
Cook Biotech firmographics
Firmographics- Name
- Cook Biotech
- Legal name
- Cook Biotech Incorporated
- Website
- https://cookbiotech.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Cook Biotech develops and manufactures porcine Small Intestinal Submucosa (SIS)-based regenerative biomaterial scaffolds for soft-tissue and peripheral nerve repair, operating as a CDMO supplying OEM medical-device companies across multiple surgical specialties. The company was acquired by RTI Surgical in January 2024.
- Ownership category
- akta.pro rank
Cook Biotech industry classification
Industry- Product category
- Regenerative Biomaterials
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
- akta.pro secondary industries
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)
Keywords
Where Cook Biotech is headquartered
LocationHeadquarters
- HQ city
- West Lafayette
- HQ country
- United States
- HQ region
- North America
Markets served
Cook Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Cook Biotech product offering
Product offeringCore offering
Cook Biotech develops and manufactures biologic tissue grafts and xenograft biomaterials derived from porcine small intestinal submucosa (SIS). The SIS platform serves as a biologic scaffold used in regenerative soft tissue repair and peripheral nerve repair applications. The company supplies these SIS-based biomaterials to original equipment manufacturers (OEMs) and surgical/medical device companies for incorporation into clinical products used in tissue repair, joint reconstruction, and nerve protection procedures.
Product overview
Cook Biotech is a biotechnology company specializing in regenerative biomaterials, particularly xenograft products derived from porcine small intestinal submucosa (SIS). The company's core product platform focuses on biologic scaffolds used for soft tissue repair, nerve repair, and regenerative medicine applications. Cook Biotech's SIS technology was acquired by RTI Surgical in January/February 2024 to strengthen capabilities in regenerative soft tissue repair.
Differentiator
Problem solved
Functional benefit
Products and services
- Porcine Small Intestinal Submucosa (SIS) Products
Companies that use Cook Biotech
Customer profileSegments2 records
Ideal customer profiles1 record
Cook Biotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Cook Biotech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- RTI SurgicalcoreRTI Surgical acquired Cook Biotech in January 2024 to enhance capabilities in regenerative soft tissue repair by integrating Cook Biotech's porcine Small Intestinal Submucosa platform. This acquisition strengthened RTI Surgical's regenerative medicine and biomaterials portfolio, enabling integration of xenograft technologies into their product offerings.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Cook Biotech competitors and assessment
Company assessmentBroad incumbents
- Stryker: Major diversified medical technology company with biologics and orthopedic surgery offerings. Competes indirectly through sports medicine, orthopedics, and regenerative solutions that overlap with Cook Biotech's soft tissue repair applications.
- Coloplast: Global medical device company with wound and skin care portfolios, including biologic and advanced wound dressings. Adjacent competitor in regenerative wound healing with broader geographic and product reach.
- Smith+Nephew: Large diversified medical device company with advanced wound management, sports medicine, and biologics franchises. Overlaps with Cook Biotech's soft tissue repair applications through skin substitutes and regenerative wound products.
- RTI Surgical (Evergen): Parent company and combined entity after acquiring Cook Biotech. Operates as a global regenerative biomaterials CDMO with allograft and xenograft offerings across multiple surgical specialties — the most direct comparable given shared SIS/xenograft technology and CDMO business model.
Direct peers
- AxoGen: Focused exclusively on peripheral nerve repair with both processed nerve allografts and synthetic/conduit solutions. Directly competes with Cook Biotech's SIS-based nerve repair products in the same clinical use cases and customer segments.
- Integra LifeSciences: Broadly diversified medical device company with strong positions in regenerative technologies for neurosurgery (dural repair), peripheral nerve repair, and wound care. Overlaps with Cook Biotech's nerve repair and soft tissue scaffold applications.
- MiMedx: Sells placental tissue-based allograft products for wound care, surgical recovery, and regenerative applications. Comparable to Cook Biotech's xenograft SIS scaffolds in biologic material sourcing and regenerative soft tissue repair use cases.
- Organogenesis: Regenerative medicine company focused on advanced wound care and surgical biologics (skin substitutes and regenerative tissue products). Closely comparable to Cook Biotech's biologic scaffold approach for soft tissue and wound healing applications.
- LifeNet Health: Non-profit tissue banking and regenerative medicine organization providing allograft and xenograft biomaterials for surgical and wound care applications. Highly comparable as an OEM-style biomaterials supplier in the same value chain as Cook Biotech.
Regional players
- Conmed: Medical device company serving orthopedic, sports medicine, and general surgery markets with an expanding biologics portfolio. Comparable channel/customer overlap with Cook Biotech's OEM surgical customers, particularly in sports medicine and orthopedics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Cook Biotech social profiles
Digital presenceCook Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cook Biotech leadership team
Management profileNumber of profiles
Cook Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cook Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cook Biotech
What does Cook Biotech do?
Cook Biotech develops and manufactures biologic tissue grafts and xenograft biomaterials derived from porcine small intestinal submucosa (SIS). The SIS platform serves as a biologic scaffold used in regenerative soft tissue repair and peripheral nerve repair applications. The company supplies these SIS-based biomaterials to original equipment manufacturers (OEMs) and surgical/medical device companies for incorporation into clinical products used in tissue repair, joint reconstruction, and nerve protection procedures.
Is Cook Biotech a public or private company?
Cook Biotech is a private company. It is classified as corporate owned and is currently acquired.
When was Cook Biotech founded?
Cook Biotech was founded in 1998. It employs 101 to 250 people.
Where is Cook Biotech based?
Cook Biotech is headquartered in West Lafayette, United States, in the North America region.
Who are Cook Biotech's main competitors?
Broad incumbents on record are Stryker, Coloplast, Smith+Nephew and RTI Surgical (Evergen). Direct peers are AxoGen, Integra LifeSciences, MiMedx, Organogenesis and LifeNet Health. Conmed is listed as a regional player.
Does Cook Biotech have an API?
No public API is recorded for Cook Biotech.
What industry is Cook Biotech in?
Cook Biotech's product category is Regenerative Biomaterials. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 2836.